Some investors asked on the investor interaction platform: covid-19 drugs of yanyiye in Japan are polypeptides. Is it consistent with the development path of the company? Has your company supplied API to yanyiye? thank you.
Hybio Pharmaceutical Co.Ltd(300199) ( Hybio Pharmaceutical Co.Ltd(300199) . SZ) said on the investor interaction platform on March 16 that Hybio Pharmaceutical Co.Ltd(300199) has focused on polypeptide drugs for more than 20 years and has the conditions and capacity for large-scale production of polypeptide APIs and polypeptide preparations. The polypeptide API factory built by our company in Wuhan is designed and constructed according to the GMP requirements of China, the United States and Europe, and the production capacity of phase I API reaches 500kg / year. At present, the company’s polypeptide API is stably supplied and sold to the United States, Europe, the association of Southeast Asian Nations and other countries. It is understood that encitrelvir, covid-19 drug of yanyeyi, is not a polypeptide drug, and the company has no intention to develop non peptide chemical intermediates of yanyeyi for the time being.
